Glutamate transporter SLC1A6 promotes resistance to immunotherapy in cancer

Abstract Background Resistance to immune checkpoint inhibitors remains a significant challenge in the treatment of cancer. Emerging evidence suggests that metabolic reprogramming plays a crucial role in tumor metabolism and progression. Our study strived to investigate the role and underlying mechan...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Chenchen Li, Yi Lin, Haoran Zheng, Hengda Zeng, Longhao Xu, Daqin Wu, Jianwen Lao, Peicong Cai, Shuai Liang, Chunhui Wang, Tianxin Lin, Wenlong Zhong
Formato: Artigo
Idioma:Inglês
Publicado em: Springer 2025-06-01
Colecção:Cancer Immunology, Immunotherapy
Assuntos:
Cancer treatment
SLC1A6
Immunotherapy
T cells
Acesso em linha:https://doi.org/10.1007/s00262-025-04074-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados